Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Q2 net loss widens to $9.6 million; cash at $138.3 million

Negative Impact 3 of 5 earnings Written later

SELLAS reported a second-quarter 2026 net loss of $9.6 million, or $0.05 per share, up from $6.6 million, or $0.07 per share, a year earlier, as research and development and general and administrative expenses rose. Cash and cash equivalents were $138.3 million at June 30, 2026, up from $71.8 million at December 31, 2025, and the company said the final analysis of its Phase 3 REGAL trial will follow the 80th event.

Key points

  • Q2 2026 net loss $9.6 million ($0.05 per share) vs. $6.6 million ($0.07 per share) in Q2 2025
  • R&D expenses $6.3 million vs. $3.9 million; G&A expenses $4.4 million vs. $3.0 million
  • Cash and cash equivalents $138.3 million at June 30, 2026, vs. $71.8 million at December 31, 2025
  • Phase 3 REGAL final analysis to follow the pre-specified 80th event; SLS009 Phase 2 topline data expected in Q4 2026

The filing

CompanySELLAS Life Sciences Group, Inc. (SLS)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:07 PM ET
Accession number0001390478-26-000013

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.